Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow ...

Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

Sanofi’s Sarclisa shows significant Phase III results for multiple myeloma, delivering deeper and longer-lasting responses in ...

The phase 3 IMROZ trial showed isatuximab plus VRd and Rd maintenance improved MRD negativity and responses versus VRd alone ...

New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th ...

New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MRD negativity rates in transplant-ineligible NDMM patients versus VRd alone New detailed results from the ...

Results support the benefit of Sarclisa-based combinations to patients in the front-line setting and the ongoing use of MRD negativity as a potential surrogate endpoint for PFS in MM research Paris, ...

Increases credit facility by $80M to $500M and extends term to December 2028 Ability to seek incremental commitments up to an additional $100M, subject to predetermined conditions Provides increased ...